PDZ1 Domain inhibitor peptide
Novel cyclic peptide that disrupts interaction between GluR6 and the postsynaptic density protein 95 (PSD-95). Competes with the C-terminus of GluR6 for binding to the PDZ1 domain of PSD-95. Inhibits clustering of kainate receptors.
(Modifications: Ala-6 = β-Ala, Cyclized = Lys-3 - Ala-6))
|Storage||Desiccate at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solubility||Soluble to 1 mg/ml in 5% acetonitrile / water and to 4 mg/ml in DMSO|
Preparing Stock Solutions
The following data is based on the product molecular weight 819.95. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.22 mL||6.1 mL||12.2 mL|
|5 mM||0.24 mL||1.22 mL||2.44 mL|
|10 mM||0.12 mL||0.61 mL||1.22 mL|
|50 mM||0.02 mL||0.12 mL||0.24 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Piserchio et al (2004) Targeting specific PDZ domains of PSD-95: structural basis for enhanced affinity and enzymatic stability of a cyclic peptide. Chem.Biol. 11 469 PMID: 15123241
If you know of a relevant reference for PDZ1 Domain inhibitor peptide, please let us know.
Keywords: PDZ1 Domain inhibitor peptide, supplier, Disrupts, interaction, between, GluR6, PSD-95, PDZ1, domain, Glutamate, Kainate, Receptors, iGluR, Ionotropic, Kainate, Receptors, Kainate, Receptors, Tocris Bioscience
Citations for PDZ1 Domain inhibitor peptide
Citations are publications that use Tocris products.
Currently there are no citations for PDZ1 Domain inhibitor peptide. Do you know of a great paper that uses PDZ1 Domain inhibitor peptide from Tocris? If so please let us know.
Literature in this Area
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.